Hepatitis by Glyburide
DOI:
https://doi.org/10.35954/SM2014.33.1.4Keywords:
Glyburide; Hepatitis, Viral, Human; Drug-Induced Liver InjuryAbstract
Presentation of a clinical case of hepatic toxicity due to the use of sulfonylureas.
Anamnesis
The patient was 60 years old, male, retired, living alone. He was admitted as an emergency patient on January 29, 2007 and the reason for consultation was jaundice.
Present illness: he started four days before admission with choluric urine, without acholia, pruritus or scratching lesions. On the day of admission she noticed yellow skin coloration. She did not present contact with rodents, fever or accompanying viral symptoms.
Personal history: Diabetes Mellitus Type 2 of 8 years of evolution, and for 3 years she has been receiving glibenclamide at a dose of 10 mg divided into 2 doses with the main meals, with few controls. He has no clinical repercussions both micro and macroangiopathic of diabetes. In addition, he is obese, dyslipidemic without treatment with oral lipid-lowering agents, does not smoke and is not hypertensive.
He is a former etilist, who stopped smoking many years ago and has a probable hepatic steatosis diagnosed by ultrasound; he has benign prostatic hyperplasia, with prostatic biopsy puncture complicated with prostatitis and repeated urinary infections and several abdominal surgeries of appendectomy and herniorrhaphy.
Received for review: August 2014.
Accepted for publication: October 2014.
Contact e-mail: piedranoble@hotmail.com
Downloads
References
(1) Topliss D, Isaacs D, Lander C, et. al. Harmful interactions. Trimethroprim/sulphamethoxazole with glibenclamide. Aust Adv Drug Reactions Bull 2003; 22(6): 21-4.
(2) Davis SN, Granner DK. Insulina, fármacos hipoglucemiantes orales y propiedades farmacológicas del páncreas endócrino. En: Goodman y Gilman. Las Bases Farmacológicas de la Terapéutica. v. 2. 9a. ed. México, D.F.: McGraw-Hill, 1996. p.1603-05.
(3) Mandell GL, Petri Jr. WA. Sulfonamidas, trimetropim-sulfametoxazol, quinolonas y fármacos contra infecciones de las vías urinarias. En: Goodman y Gilman. Las Bases Farmacológicas de la Terapéutica. v. 2. 9a. ed. México, D.F.: McGraw-Hill, 1996. p. 1123-29.
(4) Van-Basten JP, Van Hoek B, Zeijen R. Glyburide-induced cholestatic hepatitis and liver failure case-reported review of de literature. Neth J Medicine 1992; 40 (5-6): 305-7.
(5) Pérez Roldán F, Aguirre A, Bañares R. Hepatitis colestásica por glibenclamida en pacientes con infección crónica por virus de la hepatitis C. Revista Española de Diagnóstico de Enfermedades digestivas y hepáticas 1995; 87 (2): 174-6.
(6) Dourakis SP, Tzemanakis E, Sinani C, et. al. Gliclazide-induced acute hepatitis. European J Gastroenterol Hepatol 2000; 12(1): 119.
(7) Chounta A, Zouridakis S, Ellinas C, et. al. Cholestatic liver injury after glimepiride therapy. J Hepatol 2005; 42 (6): 944-6.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
